Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genfar

- PMLiVE

All eyes on pharma in Brazil

With a large population, a growing economy and a well-established healthcare system, Brazil is high on the list for most companies looking to expand into emerging markets.

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

Sanofi Israel crowdsources new diabetes app

Collaborates with online patient network Camoni

- PMLiVE

Infographic: Pharma investment in Indonesia

Pharma deals in the region since the introduction of Decree 1010 to force companies to manufacture products locally

- PMLiVE

Pharma investment in Indonesia

Healthcare reforms open up huge potential in the market to companies with a carefully tailored expansion strategy

- PMLiVE

A tailored approach to the BRIC markets

Patience, long-term thinking and strategies that are tailored to each market are key to pharma success in the BRIC countries and other emerging markets

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

- PMLiVE

Sanofi CEO Viehbacher to head EFPIA

Assumes presidency at European trade body

- PMLiVE

ADA: Sanofi eyes 2014 submissions for Lantus successor

Releases first phase III data for U300 formulation of insulin glargine

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

EU flag

EC fines pharma companies €146m for generic Celexa delay

Lundbeck, Alpharma, Merck KGaA, Generics UK, Arrow and Ranbaxy all hit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links